BRPI0507518A8 - Inibidor de hiperplasia vascular da íntima - Google Patents

Inibidor de hiperplasia vascular da íntima

Info

Publication number
BRPI0507518A8
BRPI0507518A8 BRPI0507518A BRPI0507518A BRPI0507518A8 BR PI0507518 A8 BRPI0507518 A8 BR PI0507518A8 BR PI0507518 A BRPI0507518 A BR PI0507518A BR PI0507518 A BRPI0507518 A BR PI0507518A BR PI0507518 A8 BRPI0507518 A8 BR PI0507518A8
Authority
BR
Brazil
Prior art keywords
inhibitor
hydrogen atom
intimal
hyperplasia
vascular hyperplasia
Prior art date
Application number
BRPI0507518A
Other languages
English (en)
Inventor
Nishiyama Hiroshi
Shudo Norimasa
Tsuruzoe Nobutomo
Original Assignee
Nissan Chemical Ind Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Ind Ltd
Publication of BRPI0507518A publication Critical patent/BRPI0507518A/pt
Publication of BRPI0507518A8 publication Critical patent/BRPI0507518A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDOR DA HIPERPLASIA VASCULAR DA ÍNTIMA. A presente invenção refere-se a fornecer um inibidor de hiperplasia da íntima útil para a prevenção da restenose após a angioplastia coronariana transluminal percutânea (PTCA) ou a colocação de stent vascular ou o tratamento do seu progresso. Um inibidor da hiperplasia da íntima contendo um composto 3(2H) - piridazinona representado pela fórmula (I): na qual cada um dos R1, R2 e R3 é independentemente um átomo de hidrogênio ou um grupo alquila-C1-6, X é um átomo de halogênio, um grupo ciano ou um átomo de hidrogênio, Y é um átomo de halogênio, trifluorometila ou um átomo de hidrogênio e A é um alquileno-C1-8 que pode ser substituído com um grupo hidroxila ou um sal farmacologicamente aceitável do mesmo.
BRPI0507518A 2004-02-09 2005-02-02 Inibidor de hiperplasia vascular da íntima BRPI0507518A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004032551 2004-02-09
PCT/JP2005/001518 WO2005074938A1 (ja) 2004-02-09 2005-02-02 血管内膜肥厚抑制薬

Publications (2)

Publication Number Publication Date
BRPI0507518A BRPI0507518A (pt) 2007-07-03
BRPI0507518A8 true BRPI0507518A8 (pt) 2015-12-01

Family

ID=34836093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507518A BRPI0507518A8 (pt) 2004-02-09 2005-02-02 Inibidor de hiperplasia vascular da íntima

Country Status (13)

Country Link
US (2) US20070161642A1 (pt)
EP (1) EP1714654A4 (pt)
JP (1) JP4783152B2 (pt)
KR (1) KR20070029133A (pt)
CN (1) CN100506230C (pt)
AU (1) AU2005210326B2 (pt)
BR (1) BRPI0507518A8 (pt)
CA (1) CA2553915C (pt)
HK (1) HK1098377A1 (pt)
IL (1) IL176795A (pt)
RU (1) RU2339381C2 (pt)
TW (1) TWI357409B (pt)
WO (1) WO2005074938A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723362B2 (en) * 2004-01-08 2010-05-25 Syngenta Crop Protection, Inc. Pesticidal heterocyclic dihaloallyl compounds
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
FR2948939B1 (fr) * 2009-08-05 2013-03-22 Pf Medicament Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA27031A1 (uk) * 1990-04-25 2000-02-28 Ніссан Кемікал Індастріз Лтд Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові
JP3666042B2 (ja) * 1994-01-25 2005-06-29 日産化学工業株式会社 ピリダジノン誘導体
ATE192741T1 (de) * 1994-01-25 2000-05-15 Nissan Chemical Ind Ltd Pyridazinon-derivate
TW338037B (en) * 1995-10-05 1998-08-11 Otsuka Pharma Co Ltd Carbostyril derivatives possessing platelet aggregation inhibitory activity, antithrombotic activity, intima thinkening, inhibitory activity and phosphoriesterase inhibitory activity, their preparation and pharmaceutical composition
JP2964029B2 (ja) * 1995-10-05 1999-10-18 大塚製薬株式会社 カルボスチリル誘導体
KR100559192B1 (ko) * 1997-08-28 2006-03-13 닛산 가가쿠 고교 가부시키 가이샤 혈관신생 촉진제 및 혈관신생 작용증강제
AU5445699A (en) * 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Remedies for spinal canal stenosis
EP1157694A4 (en) * 1998-12-07 2002-08-28 Nissan Chemical Ind Ltd REMEDIES OF THE ERECTIONAL DISORDER
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Also Published As

Publication number Publication date
AU2005210326A1 (en) 2005-08-18
IL176795A (en) 2013-01-31
US20090155187A1 (en) 2009-06-18
RU2339381C2 (ru) 2008-11-27
CN1905882A (zh) 2007-01-31
CA2553915C (en) 2010-06-01
US20070161642A1 (en) 2007-07-12
BRPI0507518A (pt) 2007-07-03
RU2006132389A (ru) 2008-03-20
WO2005074938A1 (ja) 2005-08-18
JPWO2005074938A1 (ja) 2007-09-13
AU2005210326B2 (en) 2009-10-22
HK1098377A1 (en) 2007-07-20
KR20070029133A (ko) 2007-03-13
TWI357409B (en) 2012-02-01
CA2553915A1 (en) 2005-08-18
EP1714654A1 (en) 2006-10-25
CN100506230C (zh) 2009-07-01
JP4783152B2 (ja) 2011-09-28
IL176795A0 (en) 2006-10-31
EP1714654A4 (en) 2011-02-16
TW200530218A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
Palmer et al. Structure–activity relationships for 2-anilino-6-phenylpyrido [2, 3-d] pyrimidin-7 (8H)-ones as inhibitors of the cellular checkpoint kinase Wee1
BRPI0507518A8 (pt) Inibidor de hiperplasia vascular da íntima
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
CA2557576A1 (en) Novel benzothiazepine and benzothiepine compounds
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
TW200617602A (en) Resist composition for EUV and process for forming resist pattern
BRPI0512790A (pt) derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
DE60013130D1 (de) Konjugate von ascorbinsäure und phytosterolen oder phytostanolen und ihre verwendung zur behandlung von gefässkrankheiten
NO20072688L (no) Aminpyridinderivat med aurora A-selektiv inhiberende virkning
ATE512154T1 (de) Kondensiertes pyrimidinderivat und xanthinoxidaseinhibitor
BRPI0515498A (pt) inibidores de dna-pk
AU2002221080A1 (en) Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
TW200801009A (en) Cdks inhibitor combinations
DK1452528T3 (da) Xanthinoxidaserinhibitorer
NO974280L (no) Intima hypertrofiinhibitorer
Myers et al. Potent quinoxaline-based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR exploration and effective bioisosteric replacement of a phenyl substituent
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
BRPI0713333A2 (pt) Potencializador de terapia de radiação
BR0211203A (pt) Acilsemicarbazidas como inibidores de cinase dependente de ciclina úteis como agentes anti-câncer e anti-proliferativos
GT200700075A (es) Derivados de eter diarilico y usos de los mismos
Meyer et al. Synthesis and pharmacological action of 3-amino-2, 1-benzisothiazoles
BR0316785A (pt) Derivados de 4-pirimidona-3-substituìdos
DE69200757D1 (de) Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NISSAN CHEMICAL INDUSTRIES LTD (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B11T Dismissal of application maintained [chapter 11.20 patent gazette]